China's Innovation Moment

From cross-border deals to newcos, faster clinical data is fueling the China innovation story, turning biopharmas from Shanghai to Beijing into global players. Multinational pharma and Western VCs have been the first to capitalize, sourcing innovation from China at record levels.

But testing faster in humans is also a recipe for Western and Asia biotechs to de-risk their own compounds, working with China partners.

This October, BioCentury, BayHelix and Insights Partner McKinsey & Company invite you to visit Shanghai for the 12th China Healthcare Summit. Get a firsthand look at China's biotech ecosystem and build your network with the right biopharmas, investors and CDMOs.

What Will I Learn? 

• How are China biotechs generating faster clinical data for their assets?

• What policies have China regulators adopted to help accelerate R&D?

• How can I source innovation from China?

• How can China de-risk Western and Asia assets via faster clinical data?

• What are the top China assets available for licensing or NewCos?

• Where is China innovation heading next on targets, modalities and indications?

• Which CDMOs and service providers can help accelerate my pipeline?

• What licensing and NewCo opportunities are available in Korea, Singapore and other emerging Asia markets?